Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 3/20 | 0.31 |
| ▸ | GSR | P00390 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3212609 | 1.00 | CYP2C9 (0.38) | CYP2C9FUCA1GSRCA2GBA1 | |
| SCHEMBL3200233 | 0.88 | HSD17B10 (0.35) | CYP2C9 | |
| SCHEMBL3211915 | 0.88 | HSD17B10 (0.35) | CYP2C9 | |
| SCHEMBL3200224 | 0.88 | HSD17B10 (0.35) | CYP2C9 | |
| SCHEMBL23950144 | 0.79 | — | — | |
| SCHEMBL1557908 | 0.77 | CYP2C9 (0.35) | CYP2C9 | |
| SCHEMBL1557910 | 0.77 | CYP2C9 (0.35) | CYP2C9 | |
| SCHEMBL15973517 | 0.76 | CYP2C9 (0.53) | CYP2C9GSRCA2 | |
| SCHEMBL25612031 | 0.76 | — | — | |
| SCHEMBL15233283 | 0.75 | CYP2C9 (0.33) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710077-B2 | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-04-29 | — | — | US | disclosed |
| EP-2102164-B1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | SANOFI AVENTIS (FR) | 2010-12-01 | — | — | EP | disclosed |
| US-20100056553-A1 | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
| EP-2102164-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008077556-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056553-A1 | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | CYP2C9 4616/4885FUCA1 2350/4885GSR 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.